Monthly Archives: February 2016

This blog was written by Jose-Carlos Gutiérrez-Ramos, CEO of Synlogic, as part of the “From The Trenches” feature of LifeSciVC. When I was invited to contribute to this blog, I was determined to write first about patients with Rare Diseases and

Biotech and the overall equity markets have been under siege the past few months from macro forces, like oil and the economy, as well as sector-specific concerns like drug pricing. After watching the carnage in 2016 wreck havoc with small

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. After a long, challenging period for CNS R&D – marked by late-stage clinical failures, mass layoffs, and limited early-stage

The equity markets have softened tremendously in recent weeks and the NASDAQ Biotech Index has swooned to levels last held in late 2014, in line with other equity indices like the S&P500.  Triggered by significant and negative macro forces, this

This blog was written by Bill Marshall, CEO of MiRagen Therapeutics in Boulder, CO, as part of the “From The Trenches” feature of LifeSciVC. Dictionary.com defines “outlier” as: (1) something that lies outside the main body or group that it